The potential overlapping populations for treatment with belimumab and rituximab using current NHS England and National Institute for Health and Care Excellence Guidelines in England and Wales

Rheumatology (Oxford). 2017 Jun 1;56(6):1041-1043. doi: 10.1093/rheumatology/kex044.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • England
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Lupus Erythematosus, Systemic / drug therapy*
  • Practice Guidelines as Topic
  • Rituximab / therapeutic use*
  • Wales

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunosuppressive Agents
  • Rituximab
  • belimumab